The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background/aims: Accurate information on harms arising from medical interventions is essential for assessing benefit–risk ratios. Since 2004, there has been an extension of the Consolidated Standards of Reporting Trials statement for reporting harms data in publications on randomized clinical trials. The objective of our study was to assess the quality of this reporting from academic randomized clinical trials on drugs. Methods: We searched for articles on randomized clinical trials funded between 2004 and 2008 by the “Programme Hospitalier de Recherche Clinique.” We included all published randomized clinical trials that assessed drugs. Harm-related data were extracted and compared with the Consolidated Standards of Reporting Trials Harms extension, and the space in the articles devoted to harms data was measured. Results: In total, 37 randomized clinical trials met the inclusion criteria. The median harm score was 9/18. In 73.0% of the randomized clinical trials, the reporting of adverse events was selective. Less than 50% of articles provided information on reasons for drug discontinuation that were related to adverse events. The score and the space allocated to harms were higher in antineoplastic and immunomodulating drugs randomized clinical trials, while the median proportion of the space in the results section allocated to harms was 16.8%. In 67.6% of the articles, the space allocated to the authors’ list and affiliations was greater than the space in the results section allocated to descriptions of harms. No significant improvement in the score or the space allocation was observed during the study period. Conclusion: Reporting of harms in French academic drug randomized clinical trials is suboptimal; moreover, this shortcoming is a critical barrier to evaluating the benefit–risk ratio of drug randomized clinical trials. Thus, the authors should be encouraged to adhere to the Consolidated Standards of Reporting Trials Harms extension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another important reason for data extraction errors might be the poor reporting of adverse events in randomised controlled trials, which have varying terminology, poorly defined categories, and diverse data sources. 30 31 32”
From Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study (2022) · cites this paper as [32]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593 · cited 2×
“In particular, the recommendations included (1) mentioning harms in the title or abstract if safety is an objective, (2) clarifying how the information related to the AEs was collected, (3) describing discontinuations due to harms, (4) presenting frequencies per study arm and type of AE, and (5) including a balanced d…”
BackgroundLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Jabre, P., Combes, X., Lapostolle, F., Dhaouadi, M., Ricard-Hibon, A., Vivien, B., Bertrand, L., Beltramini, A., Gamand, P., Albizzati, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60949-1 · Cited by 562
Hopewell, S., Dutton, S., Yu, L.-M., Chan, A.-W., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c723 · Cited by 504 · cited 1×
“In the same manner, although the CONSORT statement had received widespread attention, adherence to it is still found to be incomplete, even though improvements concerning certain recommendations during successive years have been highlighted.(65,66) The assessment was performed by two independent persons using a standa…”
MethodBernard, L., Dinh, A., Ghout, I., Simo, D., Zeller, V., Issartel, B., Le Moing, V., Belmatoug, N., Lesprit, P., Bru, J.-P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61233-2 · Cited by 494
Research works printed but not linked: 1
- Rozenberg P, 2012, Am J Obstet Gynecol, 206, 206
Cited by
Junqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · BMJ · doi:10.1136/bmj-2022-073725 · Cited by 281
Analysis and reporting of adverse events in randomised controlled trials: a review
Phillips, R., Hazell, L., Sauzet, O., & Cornelius, V. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024537 · Cited by 228
Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study
Xu, C., Yu, T., Furuya-Kanamori, L., Lin, L., Zorzela, L., Zhou, X., Dai, H., Loke, Y., & Vohra, S. (2022) · BMJ · doi:10.1136/bmj-2021-069155 · Cited by 82
Junqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.04.005 · Cited by 67
Phillips, R., Sauzet, O., & Cornelius, V. R. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01167-9 · Cited by 40
“Methods that propose graphical approaches to view single or multiple AEs as the principal analysis method.”
BackgroundInfluential
Metadata
- Authors
- Favier, R., & Crépin, S.
- Affiliations
- Centre Hospitalier Universitaire de Limoges (FR)
- Corresponding author
- Crépin, Sabrina
- ORCID
- Crépin, Sabrina
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2018-03-02
- Volume
- 15
- Issue
- 3
- Pages
- 257-267
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2790844534
- Cited by
- 19
- References
- 66
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Clinical Trials (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- harms reporting, adverse events, risk-benefit assessment, clinical drug trials, reporting quality, anticancer agents, immunomodulators
- MeSH terms
- Data Accuracy, Adult, Child, Preschool, France, Humans, Periodicals as Topic, Publishing, Research Design, Randomized Controlled Trials as Topic, Adverse Drug Reaction Reporting Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme. https://app.cochat.ai/papers/10.1177/1740774518760565
- The paper
- Favier, R., & Crépin, S. (2018). The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme. Clinical Trials. https://doi.org/10.1177/1740774518760565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.